sodium oxybate (xyrem) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Sodium oxybate is the sodium salt of gamma-hydroxybutyrate (GHB), an endogenous metabolite of gamma-aminobutyric acid (GABA) a major inhibitory neurotransmitter. Evidence suggests a role for GHB as a neuromodulator/neurotransmitter. Under endogenous conditions and concentrations, and depending on the cell group affected, GHB may increase or decrease neuronal activity by inhibiting the release of neurotransmitters that are co-localised with GHB. After exogenous administration, most of the observed behavioural effects appear to be mediated via the activity of GHB at GABA(B) receptors, as long as the concentration is sufficient to elicit binding, which does not happen at endogenous concentrations. Xyrem (sodium oxybate) oral solution is indicated for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness (EDS) in narcolepsy.   NCATS

  • SMILES: OCCCC(=O)O
  • InChIKey: SJZRECIVHVDYJC-UHFFFAOYSA-N
  • Mol. Mass: 104.11
  • ALogP: -0.16
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

3-carboxypropoxy acid | 3-hydroxybutyrate | 4-hydroxybutanoate | 4-hydroxybutanoic acid | 4-hydroxy-butyric acid | 4-hydroxybutyric acid | gamma-hydroxybutyrate | gamma hydroxybutyric acid | gamma-hydroxybutyric acid | gammahydroxybutyric acid | ghb | hydroxybutyrate | oxybate | oxybate sodium | oxy-n-butyric acid | sodium hydroxybutyrate | sodium oxybate | wy-3478 | xyrem | γ-hydroxybutyric acid

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue